Poly (ADP‐ribose) polymerase (PARP) inhibitors are increasingly being studied as cancer drugs, as single agents or as a part of combination therapies. Imaging of PARP using a radiolabeled inhibitor has been proposed for patient selection, outcome prediction, and dose optimization of novel PARP‐targeting agents.
We have synthesised the fluorine-18 radiolabelled version of olaparib, an FDA-approved PARP inhibitor, and tested it in vitro and in vivo with promising results, and are now moving the first steps towards the clinical evaluation of this novel imaging agent.